Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States

BACKGROUND: Pembrolizumab, a programmed cell death-1 (PD-1) inhibitor, has recently gained prominence as a second-line treatment for recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC). This study compares the acceptance and different influencing factors of pembrolizumab in th...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Manag Res
मुख्य लेखकों: Liu, Maobai, Han, Sijie, Zheng, Bin, Cai, Hongfu, Yang, Jing, Zhuang, Qian, Li, Na
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Dove 2019
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858623/
https://ncbi.nlm.nih.gov/pubmed/31814756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S226243
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन